UNSPSC 51262901: Pindolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BJ4HF6IU1D, chemically known as 2-propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)- but generally known as pindolol, which bears US NIH Compound Identifier 4828. European Medicines Agency schedules Pindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09854MIG.

UNSPSC 51262901 Pindolol is a Commodity code nominally describing a specific beta-blocker pharmaceutical, but recent state and local opportunities tagged under it show minimal activity aligned with the code's abstract definition. The single concrete solicitation on record—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—addresses opioid-overdose response supplies rather than cardiovascular medication, and a parallel Request for Information from the Texas Health and Human Services Commission concerns pharmacy benefit management and direct-to-manufacturer prescription contracting, neither of which relates to pindolol procurement. The code appears to capture a narrow pharmaceutical product line with little recent state or local buying activity; when opportunities do surface, they often reflect broader health-system or pharmacy program initiatives rather than targeted pharmaceutical acquisitions under the code's nominal scope.

Activity concentrating in Florida and Texas reflects opportunistic tagging rather than sustained procurement patterns. The Seminole County opportunity (due July 26, 2023, through competitive IFB) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and included FEMA compliance requirements and a two-year initial term with one-year renewal option. The Texas HHS RFI (due April 3, 2026) was exploratory market research rather than a formal solicitation, gathering vendor capabilities on direct-to-manufacturer prescription contracting before eventual formal RFP release. Neither opportunity directly aligns with pindolol procurement. Business development professionals should treat this code as currently inactive for genuine pindolol purchasing; verification of coding accuracy and tracking of future opportunities under this Commodity code is warranted before resource allocation.